Hip osteoarthritis: short-term efficacy and safety of viscosupplementation by hylan G-F 20. An open-label study in 22 patients.

Abstract

UNLABELLED:

We studied the short-term safety and efficacy of intraarticular hylan G-F 20 (Synvisc) in patients with symptomatic hip osteoarthritis.

METHODS:

In this open-label prospective study, patients who had hip osteoarthritis with a visual analog pain scale score greaterthan 40/100 and a Lequesne index greater than 6 received one or two intra-articular injections of hylan G-F 20 under fluoroscopic guidance. The patients were evaluated once a month. A response was defined as a 50% decrease in the Lequesne score after 1 month as compared to baseline.

RESULTS:

Thirty injections were performed in 22 patients with a mean age of 54 years. The response rate was 50% (11/22) after the first injection. Five of the 11 patients who failed to respond to the first injection received a second injection on day 30; two had a response, yielding a cumulative response rate of 13/22. In the six patients followed up for more than 6 months, the improvement was sustained. Short-term safety was satisfactory, with a self-limited exacerbation of pain during the first few days in three patients but no infections or other side effects.

• Authors: Olivier Brocq, Gali Tran, Véronique Breuil, Christian Grisot, Philippe Flory, Liana Euller-Ziegler
• Journal: Joint bone spine (Joint Bone Spine) Vol. 69 Issue 4 Pg. 388-91 (Jun 2002) ISSN: 1297-319X [Print] France
• PMID: 12184436 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• hylan
• Hyaluronic Acid

Topics

• Female
• Hip Joint
• Humans
• Hyaluronic Acid (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Injections, Intra-Articular
• Male
• Middle Aged
• Osteoarthritis (drug therapy, physiopathology)
• Pain Measurement
• Prospective Studies
• Safety
• Treatment Outcome